Antibody-related damage and CD8+ T cell-mediated cytotoxicity have been proposed as underlying mechanisms, affecting not only muscle function but also potentially contributing to the systemic and neurological manifestations observed in MG patients [13–15]. The gene discussed is CD8A; the disease is myasthenia gravis.